DALIYA CHANDROTH: Open Payments
NPI 1730738428 · FAIR LAWN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,080 in 131 payments from 14 companies in 2025. Trend: 2023 $1,028 · 2024 $1,728 · 2025 $2,080
Food & beverage: $2,080
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $340 |
| Axsome Therapeutics, Inc. | 15 | $286 |
| Otsuka America Pharmaceutical, Inc. | 16 | $264 |
| Teva Pharmaceuticals USA, Inc. | 16 | $228 |
| Supernus Pharmaceuticals, Inc. | 17 | $223 |
| ABBVIE INC. | 14 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $146 |
| Alkermes, Inc. | 7 | $114 |
| E.R. Squibb & Sons, L.L.C. | 6 | $96 |
| Lundbeck LLC | 4 | $68 |
Products named: INGREZZA, REXULTI, Auvelity, Qelbree, AUSTEDO XR, VRAYLAR, CAPLYTA, LYBALVI.
Industry payments across NJ — which companies pay providers there.
